The Company posted Net Sales growth of 12% compared to the previous quarter, while Profit before Investment Income and Taxes grew by 13% on a comparable basis.
Commenting on the performance, Dr. Hasit B. Joshipura, Managing Director, said, Sales during the quarter have shown growth across mass, mass speciality, vaccines and speciality therapies. Recent launches of Tykerb for refractory breast cancer, Benitec an anti-hypertensive drug from Daiichi Sankyo and Cervarix for cervical cancer are making steady progress. Vaccines have recorded strong growth with the rotaviral diarrhea vaccine tracking ahead of plan".